FDA Approves Akeega (niraparib and abiraterone acetate) for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
Drugs.com,
HORSHAM, Pa., August 11, 2023 – The Janssen Pharmaceutical Companies of Johnson
HORSHAM, Pa., August 11, 2023 – The Janssen Pharmaceutical Companies of Johnson
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest…
Approval for AKEEGATM is based on results from the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study…
Share on PinterestA new combination therapy for prostate cancer shows promise in clinical trials.
BEERSE, Belgium, 24 February 2023 - The Janssen Pharmaceutical Companies of Johnson
If approved, niraparib in combination with abiraterone acetate (AA), will be the first dual action tablet (DAT) available in…
BEERSE, BELGIO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Le aziende farmaceutiche Janssen di Johnson
SAN FRANCISCO, Feb. 16, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO…
SAN FRANCISCO, Feb. 16, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO…
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO…
SAN FRANCISCO, Feb. 16, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO…
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO…
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO…
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU, - The…
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO…
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO…
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO…
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO…
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO…
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO…
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO…
SAN FRANCISCO, Feb. 16, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
SAN FRANCISCO, Feb. 16, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO…
Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO…